BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,130 filers reported holding BAXTER INTL INC in Q1 2022. The put-call ratio across all filers is 1.41 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2022 | $213,000 | -24.2% | 3,630 | 0.0% | 0.01% | -11.1% |
Q1 2022 | $281,000 | -22.2% | 3,630 | -13.7% | 0.01% | -18.2% |
Q4 2021 | $361,000 | +6.8% | 4,205 | 0.0% | 0.01% | 0.0% |
Q3 2021 | $338,000 | -0.3% | 4,205 | 0.0% | 0.01% | 0.0% |
Q2 2021 | $339,000 | -7.6% | 4,205 | -3.4% | 0.01% | -8.3% |
Q1 2021 | $367,000 | +12.6% | 4,355 | +7.3% | 0.01% | 0.0% |
Q4 2020 | $326,000 | 0.0% | 4,057 | 0.0% | 0.01% | -7.7% |
Q3 2020 | $326,000 | -6.6% | 4,057 | 0.0% | 0.01% | -13.3% |
Q2 2020 | $349,000 | +53.7% | 4,057 | +24.8% | 0.02% | -28.6% |
Q2 2015 | $227,000 | +0.9% | 3,252 | -1.1% | 0.02% | -4.5% |
Q1 2015 | $225,000 | -35.7% | 3,289 | -31.2% | 0.02% | -37.1% |
Q4 2014 | $350,000 | +2.0% | 4,778 | 0.0% | 0.04% | -2.8% |
Q3 2014 | $343,000 | -0.6% | 4,778 | 0.0% | 0.04% | +2.9% |
Q2 2014 | $345,000 | -2.0% | 4,778 | 0.0% | 0.04% | -7.9% |
Q1 2014 | $352,000 | +3.8% | 4,778 | -1.9% | 0.04% | 0.0% |
Q4 2013 | $339,000 | +6.6% | 4,870 | +0.7% | 0.04% | -5.0% |
Q3 2013 | $318,000 | – | 4,838 | – | 0.04% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Third Point | 41,000,000 | $2,482,140,000 | 22.00% |
THUNDERBIRD PARTNERS LLP | 1,711,643 | $103,623,000 | 12.17% |
SECTOR GAMMA AS | 1,070,333 | $64,798,000 | 9.42% |
Veritas Asset Management LLP | 10,179,102 | $616,243,000 | 4.81% |
13D Management LLC | 194,807 | $11,794,000 | 4.18% |
Progressive Investment Management Corp | 78,316 | $4,741,000 | 3.69% |
Aristotle Capital Management, LLC | 6,846,307 | $414,476,000 | 3.46% |
ARGENT CAPITAL MANAGEMENT LLC | 1,394,075 | $84,397,000 | 3.37% |
Lipe & Dalton | 80,073 | $4,848,000 | 3.14% |
PURA VIDA INVESTMENTS, LLC | 125,000 | $7,568,000 | 3.00% |